Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2013; 19(46): 8543-8551
Published online Dec 14, 2013. doi: 10.3748/wjg.v19.i46.8543
Published online Dec 14, 2013. doi: 10.3748/wjg.v19.i46.8543
Ref. | Country | Study design | Inclusion period | Patients (n) | Operations | Approach | LOS (d) | Readmissions | Morbidity | Mortality | ||||
ERP | CC | ERP | CC | ERP | CC | ERP | CC | |||||||
Anderson et al[3], 2003 | United Kingdom | RCT | ND | 25 (ERP: 14, CC: 11)Cancer: 18 (72)ERP: 11, CC: 7 | RH: 14 (ERP: 9, CC: 5)LH: 11 (ERP: 5, CC: 6) | ND | 3 (2-7) | 7 (4-10)a | 0 (0) | 0 (0) | 4 (29) | 5 (45) | 0 (0) | 1 (9) |
Gatt et al[4], 2005 | United Kingdom | RCT | ND | 39 (ERP: 19, CC: 20)Cancer: 27 (69)ERP: 12, CC: 15 | RH: 10 (ERP: 5, CC: 5)AR: 15 (ERP: 5, CC: 10)Others: 14 (ERP: 9, CC: 5) | ND | 5 (4-9) | 7.5 (6-10)a | 1 (5) | 4 (20) | 9 (47) | 15 (75) | 1 (5) | 0 (0) |
Khoo et al[5], 2007 | United Kingdom | RCT | 2003-2004 | 70 (ERP: 35, CC: 35)Cancer: 70 (100) | Colonic: 47 (ERP: 22, CC: 25)Rectal: 23 (ERP: 13, CC: 10) | Open | 5 (3-37) | 7 (4-63)a | 3 (9) | 1 (3) | 9 (26) | 16 (46) | 0 (0) | 2 (6) |
Muller et al[6], 2009 | Switzerland | RCT | 2004-2006 | 151 (ERP: 76, CC: 75)Cancer: 131 (87)ERP: 67, CC: 64 | RH: 48 (ERP: 26, CC: 22)AR/LH: 101(ERP: 30, CC: 51) | Open | 5 (2-30) | 9 (6-30)a | 3 (4) | 2 (3) | 16 (21) | 37 (49)a | 0 (0) | 0 (0) |
Serclova et al[7], 2009 | Czech | RCT | 2005-2007 | 103 (ERP: 51, CC: 52)Cancer: 7 (7)ERP: 3, CC: 4IBD: 89 (86)ERP: 46, CC: 43 | Simple:(ERP: 47.1%, CC: 61.5)Multiple:(ERP: 29.4%, CC: 21.2) | Open | 7 (5-11) | 9 (7-22)a | 0 (0) | 0 (0) | 11 (22) | 25 (48)a | 0 (0) | 0 (0) |
Lee et al[13], 2011 | South Korea | RCT | 2007-2009 | 100 (ERP: 46, CC: 54)Cancer: 100 (100) | RH: 38 (ERP: 17, CC: 21)LH: 15 (ERP: 5, CC: 10)AR: 47 (ERP: 24, CC: 23) | Lap | 7 (6-8) | 8 (7-9) | 0 (0) | 0 (0) | 6 (11) | 14 (20) | 0 (0) | 0 (0) |
Vlug et al[9], 2011 | Netherlands | RCT | 200 -2009 | 400 (ERP: 193, CC: 207)Cancer: 400 (100) | RH: 179 (ERP: 80, CC: 99)LH: 221 (ERP: 120, CC: 101) | Open/lap | Open: 7 (5-11)Lap: 5 (4-8) | Open: 7 (6-13)Lap: 6 (4.5-9.5)a | 13 (7) | 14 (7) | 125 (65) | 132 (64) | 6 (3) | 4 (2) |
Wang et al[26], 2012 | China | RCT | 2006-2009 | 78 (ERP: 40, CC: 38)Cancer: 78 (100) | RH: 13 (ERP: 7, CC: 6)Sig: 34 (ERP: 18, CC:16)AR: 25 (ERP: 13, CC: 12) | Lap | 5.5 (5-6) | 7.0 (6-8)a | ND | ND | 2 (5) | 8 (21) | 0 (0) | 0 (0) |
Ref. | Country | Study design | Inclusion period | Patients (n) | Operations | Clinical effectiveness (LOS and complications) |
Lindsetmo et al[22], 2009 | United States | Prospective cohort study | 2005-2007 | 37Cancer: 17 (46)Polyp: 4 (11)Others: 16 (43) | SPS: 37 (100)Diverting ileostomy: 7 (19) | Mean LOS: 3.0 d (range 1-8 d)Overall complications: 6 (16)UTI: 1; SSI: 2Readmission < 30 d: 3 (8) |
Chen et al[27], 2011 | Taiwan | Prospective cohort study | 2007-2009 | 80Cancer: 76 (95)Benign: 4 (5) | APR: 15 (19)SPS: 65 (81)Diverting ileostomy: 32 (49) | Mean LOS: 5.0d (range 3-22)Overall complications: 11 (14)AL: 1; pelvic abscess 2; ileus: 1Readmission < 30 d: 7 (9) |
Stottmeier et al[28], 2012 | Denmark | Prospective cohort study | 2006-2009 | 102Cancer: 102 (100) | APR: 19 (19)Hartmann: 6 (6)SPS: 77 (75)Diverting colostomy: 38 (37)Diverting ileostomy: 3 (3) | Median LOS: 5 d (range 2-42 d)Overall complications: 25 (25)AL: 3; intra-abdominal abscess: 3Readmission < 30 d: 15 (15) |
Huibers et al[29], 2012 | Nether-lands | Retrospective case-control study | 2004-2009 | 76 (ERP: 43, CC: 33)Cancer: 76 (100) | APR: 24 (32)ERP: 16 (37)CC: 8 (24)SPS: 52 (68)ERP: 27 (63)CC: 25 (76) | Median LOS: (P = 0.042)ERP: 7 d (range 2-83 d)CC: 10 d (range 4-74 d)Overall complications:ERP: 17 (40)AL: 5; intra-abdominal abscess: 7CC: 9 (27)AL: 4; intra-abdominal abscess: 3Readmission < 30 d: (P = 0.421)ERP: 5 (12)CC: 6 (18) |
Lee et al[30], 2013 | South Korea | RCT | 2007-2011 | 98 (ERP: 52, CC: 46)Cancer 98 (100) | SPS: 98 (100)Diverting ileostomy: 98 (100) | Median recovery time1: (P = 0.47)ERP: 137 h (range 107-188 h)CC: 146.5 h (range 115-183 h)Overall complications: (P = 0.054)ERP: 22 (42)AL: 1; POI: 15; acute voiding difficulty: 9CC: 11 (24)AL: 1; POI: 6; acute voiding difficulty: 2Readmission < 30 d: 0 (0) |
Protocols | Lindsetmo et al[22], 2009 | Chen et al[27], 2011 | Stottmeier et al[28], 2012 | Huibers et al[29], 2012 | Lee et al[30], 2013 |
Preoperative stage | |||||
General considerations | Patient education | Patient education and ERP explanation | Thorough informationEstablishing a contract | ND | Operative risk assessmentCounseling, informed consent |
Oral bowel preparation | Yes | Yes | No (enema for left-sided tumors) | No (2 enemas) | Yes |
NPO | ND | 8 h before surgery | Fluid until 2 h before surgery | 2 h before surgery | 8 h before surgery |
Oral carbohydrate solution | No | No | No | Yes | No |
Epidural analgesia | No | No | Yes | Yes | No |
Prophylactic antibiotics | ND | Single dose | Single dose (ampicillin + metronidazole + gentamicin) | Single dose (cefalozine + metronidazole) | ND |
DVT prophylaxis | ND | ND | LMWH 2 h before surgeryCompression stockings | LMWH until discharge | ND |
Perioperative stage | |||||
Operation approach | Laparoscopic | Laparoscopic | Laparoscopic | Laparoscopic | Laparoscopic |
Anesthesia | ND | Short-acting anesthetics | Propofol, remifentanyl and muscle relaxant | ND | ND |
Fluid | ND | Perioperative fluid restriction | Avoid both hypovolemia and fluid overload | ND | ND |
Urinary drainage | Urethral catheter | Urethral catheter | Suprapubic or urethral catheter | Urethral catheter | Urethral catheter |
Nasogastric tube | Yes (orogastric tube, removed before extubation) | No | No | No | No |
Intra-abdominal drain | Rarely | Yes | No | Yes (one) | Yes (one) |
Postoperative stage | |||||
Pain control | IV PCA (12-18 h)KetorolacOral analgesia | Oral NSAIDs immediatelyafter surgeryOpioid for 1 d if needed | Epidural analgesiaParacetamol, ibuprofenOpioid if needed | Epidural analgesiaParacetamol, diclofenacOpioid avoided | IV PCA till POD 2 |
Sipping water | Immediately after surgery | Immediately after surgery | Immediately after surgery | Immediately after surgery | Immediately after surgery |
Oral food intake | POD 1 | POD 1 | Evening of the day of surgery | Liquid diet in the evening | Semi-fluid diet, POD 1 |
Removal of urinary catheter | POD 1 | POD 1 | Immediately after surgery | POD 2 | POD 3 |
Removal of intra- abdominal drain | No drain | POD 4 | No drain | POD 2 | ND |
Mobilization | As soon as possible | Immediately after surgery | Two hours after surgery | POD 1 | POD 1 |
Regular laxatives | ND | Sennoside | MgSO4 1 g two dimes daily | MgO | MgO |
Routine discharge | ND | POD 5 | POD 3 | ND | ND |
Discharge criteria | Tolerance of fluids and solid diet, adequate oral analgesia, passage of flatus or stool, adequate home support | No fever, no tachycardia, successful passage of flatus/stool, tolerance for 3 meals/d, comfort in taking oral non-opioid analgesics, independent ambulation, adequate self-care ability | Adequate bladder and bowel function, ability to drink, eat, walk without problems, manageable pain | No remaining lines or catheters, toleration of solid food, passage of stool, controllable pain, self-care ability | ND (Recovery: tolerance of diet for 24 h, analgesic-free, safe ambulation, afebrile status without major complications) |
- Citation: Kim DW, Kang SB, Lee SY, Oh HK, In MH. Early rehabilitation programs after laparoscopic colorectal surgery: Evidence and criticism. World J Gastroenterol 2013; 19(46): 8543-8551
- URL: https://www.wjgnet.com/1007-9327/full/v19/i46/8543.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i46.8543